Not All Celiac Drugs Work the Same Way

When people hear researchers are developing “drugs for celiac disease,” they often assume scientists are trying to invent a pill that allows people with celiac disease to eat gluten again.

But that’s not really how most of the research pipeline works.

Right now, scientists are pursuing four very different strategies:

Enzyme therapies – break gluten apart before the immune system recognizes it

TG2 inhibitors – block the step that makes gluten trigger the immune system

Immune tolerance therapies – attempt to retrain the immune system not to attack gluten

Barrier therapies – try to reduce the amount of gluten that crosses the intestinal lining

Over the next few weeks in this series, we’ll look at each strategy and where it stands in the drug development pipeline.

This week we start with the most intuitive idea:

What if we could simply destroy gluten before the body reacts to it?

The Basic Science

The “Lactaid for Gluten” Concept

If someone is lactose intolerant, they can take lactase, the enzyme that breaks lactose into digestible sugars.

Scientists wondered if something similar might work for gluten.

The concept behind enzyme therapies is straightforward:

Gluten enters the stomach with food. A specialized enzyme breaks gluten proteins into smaller fragments. Those fragments are no longer recognized by the immune system. The autoimmune reaction never begins.

In theory, this could protect people with celiac disease from small, accidental gluten exposures.

Think:

• cross-contamination at restaurants

• hidden gluten in sauces or seasoning blends

• labeling mistakes

• manufacturing contamination

The goal was never really “eat all the pizza you want.”

The goal was closer to:

“Reduce the damage caused by small accidental exposures.”

Why This Strategy Is So Difficult

Unfortunately, gluten is a stubborn protein.

It contains sequences rich in proline and glutamine, which make it unusually resistant to digestion. Even the enzymes naturally present in our stomach and pancreas struggle to fully break it down.

Those same resistant fragments are also the ones most likely to trigger the immune response in celiac disease.

For an enzyme therapy to work, it has to accomplish several things at once:

• survive stomach acid

• break gluten down rapidly

• destroy the immune-activating fragments completely

• do all of this before gluten reaches the small intestine

That’s a tall scientific challenge.

Pros and Cons of Enzyme Therapies

Potential Advantages

Conceptually simple

Most people immediately understand the idea of a digestive enzyme pill.

Convenient

If effective, it could be taken before meals.

Protection from accidental exposure

Many people with celiac disease are not trying to eat gluten intentionally — they’re trying to avoid being sickened by trace contamination.

An enzyme therapy could theoretically serve as a protective buffer.

Major Limitations

Gluten is hard to destroy

Many enzyme candidates have struggled to break down the most immunogenic fragments completely.

Symptom improvement does not equal intestinal protection

Several trials showed improvement in symptoms but no clear protection of the intestinal lining.

For celiac disease, preventing villous damage is the real goal.

Timing matters

If gluten reaches the small intestine before the enzyme finishes working, the immune response can still occur.

Drugs in This Category

Latiglutenase (ALV003)

Latiglutenase combines two gluten-digesting enzymes designed to break gluten proteins into smaller fragments.

Over the past decade, it has been studied in several clinical trials.

Results were mixed.

Some patients reported fewer symptoms during gluten exposure, but the studies did not consistently demonstrate protection of the small intestine when biopsies were examined.

Because preventing intestinal injury is central to treating celiac disease, enthusiasm for the drug decreased.

Latiglutenase remains an important part of the scientific story, however, because it demonstrated just how difficult it is to neutralize gluten quickly enough in the digestive tract.

TAK-062

TAK-062 is a newer enzyme therapy currently under development.

Unlike earlier approaches, this enzyme was computationally engineered specifically to target gluten proteins.

Laboratory and early human studies have shown it can rapidly degrade large quantities of gluten under stomach-like conditions.

Researchers are now studying whether that translates into meaningful protection for people with celiac disease.

TAK-062 is currently in mid-stage clinical trials (Phase 2).

Where This Strategy Stands Today

Enzyme therapies were one of the earliest drug strategies explored for celiac disease.

They remain scientifically interesting, but the results so far suggest they may be better suited as adjunct therapies rather than standalone treatments.

In other words, if enzyme drugs succeed, they may function more like a safety net against accidental exposure rather than a license to eat gluten freely.

That realization is one reason scientists have begun focusing more attention on therapies that target the immune response itself.

What This Means for People with Celiac Disease

The appeal of a “Lactaid for gluten” is obvious.

It’s simple. Logical. Easy to imagine.

But celiac disease has turned out to be far more complicated than lactose intolerance.

Destroying gluten quickly and completely inside the digestive system has proven to be an enormous biochemical challenge.

That’s why the next generation of research is shifting toward different strategies — including drugs that attempt to block the immune reaction itself.

Next week we’ll look at one of the most interesting of those strategies:

blocking the enzyme that helps make gluten dangerous in the first place.

If a pill existed that reduced the damage from accidental gluten exposure, would you take it?

Or would you still rely entirely on the gluten-free diet alone?